Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.
Gomberg-Maitland M, Badesch DB, Gibbs JSR, Grünig E, Hoeper MM, Humbert M, Kopeć G, McLaughlin VV, Meyer G, Olsson KM, Preston IR, Rosenkranz S, Souza R, Waxman AB, Perchenet L, Strait J, Xing A, Johnson-Levonas AO, Cornell AG, Pena JO, Ardeschir Ghofrani H. Gomberg-Maitland M, et al. Among authors: mclaughlin vv. J Heart Lung Transplant. 2024 Dec 5:S1053-2498(24)02009-6. doi: 10.1016/j.healun.2024.11.037. Online ahead of print. J Heart Lung Transplant. 2024. PMID: 39645016
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB. Humbert M, et al. Eur Respir J. 2023 Jan 6;61(1):2201347. doi: 10.1183/13993003.01347-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36041750 Free PMC article. Clinical Trial.
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Hoeper MM, et al. Among authors: mclaughlin vv. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. N Engl J Med. 2023. PMID: 36877098 Clinical Trial.
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
Souza R, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Lin J, Johnson-Levonas AO, de Oliveira Pena J, Humbert M, Hoeper MM. Souza R, et al. Among authors: mclaughlin vv. Eur Respir J. 2023 Sep 21;62(3):2301107. doi: 10.1183/13993003.01107-2023. Print 2023 Sep. Eur Respir J. 2023. PMID: 37696565 Free PMC article.
Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.
Rosenkranz S, Ghofrani HA, Hoeper MM, Langleben D, Hegab S, Rahner C, Richard JF, McLaughlin VV. Rosenkranz S, et al. Among authors: mclaughlin vv. J Heart Lung Transplant. 2024 Sep 3:S1053-2498(24)01807-2. doi: 10.1016/j.healun.2024.08.018. Online ahead of print. J Heart Lung Transplant. 2024. PMID: 39236972 Free article.
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.
Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Preston IR, et al. Among authors: mclaughlin vv. J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2. J Heart Lung Transplant. 2018. PMID: 29096938 Clinical Trial.
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group. Vachiéry JL, et al. Among authors: mclaughlin vv. J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22. J Heart Lung Transplant. 2019. PMID: 30522722 Free article. Clinical Trial.
208 results